A Dartmouth College investigation has concluded that H. Gilbert Welch, MD, MPH, a prominent healthcare policy researcher, committed research misconduct in connection with a breast cancer paper published in The New England Journal of Medicine in 2016; a Boston University endocrinologist, Michael Holick, MD, who had a crucial role in drafting national vitamin D guidelines, has benefitted from the industry in the amount of hundreds of thousands of dollars; 24 states have passed 37 bills this year to curb rising prescription drug costs as bipartisan efforts are forcing pharmaceutical companies to disclose and justify price increases.
A Dartmouth College investigation has concluded that H. Gilbert Welch, MD, MPH, a prominent healthcare policy researcher, committed research misconduct in connection with a breast cancer paper published in The New England Journal of Medicine (NEJM) in 2016. NEJM is not retracting the paper, saying it is an issue of authorship dispute. According to STAT News and Retraction Watch, Welch plagiarized material from a Dartmouth colleague and another researcher at a different institution, according to a June letter from the college’s interim provost. Welch has denied the allegations.
A Boston University endocrinologist, Michael Holick, MD, who had a crucial role in drafting national vitamin D guidelines, has benefitted from the industry in the amount of hundreds of thousands of dollars, according to a Kaiser Health News investigation. The list includes drugmakers, the indoor-tanning business, and Quest Diagnostics. Holick helped create a billion-dollar vitamin D sales and testing industry, with supplement sales rising to $936 million last year, a 9-fold increase over the previous decade. Physicians have embraced his message, ordering more than 10 million vitamin D tests for Medicare patients in 2016, up 547% since 2007, at a cost of $365 million.Twenty-four states have passed 37 bills this year to curb rising prescription drug costs as bipartisan efforts are forcing pharmaceutical companies to disclose and justify price increases, The New York Times reported. Drug makers are challenging the state laws as a violation of their constitutional rights. States are also trying to regulate pharmacy benefit managers. New York, Utah, Ohio, Connecticut, Nevada, California, Oklahoma, and Maryland are all trying different approaches in an effort to reduce out-of-pocket costs for consumers struggling to afford drugs that often cost thousands of dollars a month.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More